Rebecca Cook
Faculty Member
Last active: 4/15/2019

  1. Collagen density and alignment in responsive and resistant trastuzumab-treated breast cancer xenografts. Walsh AJ, Cook RS, Lee JH, Arteaga CL, Skala MC (2015) J Biomed Opt 20(2): 26004
    › Primary publication · 25700233 (PubMed) · PMC4335617 (PubMed Central)
  2. Clearance of dying cells accelerates malignancy. Vaught DB, Cook RS (2015) Oncotarget 6(28): 24590-1
    › Primary publication · 26387138 (PubMed) · PMC4694776 (PubMed Central)
  3. Bcl-2 family proteins in breast development and cancer: could Mcl-1 targeting overcome therapeutic resistance? Williams MM, Cook RS (2015) Oncotarget 6(6): 3519-30
    › Primary publication · 25784482 (PubMed) · PMC4414133 (PubMed Central)
  4. Activating PIK3CA Mutations Induce an Epidermal Growth Factor Receptor (EGFR)/Extracellular Signal-regulated Kinase (ERK) Paracrine Signaling Axis in Basal-like Breast Cancer. Young CD, Zimmerman LJ, Hoshino D, Formisano L, Hanker AB, Gatza ML, Morrison MM, Moore PD, Whitwell CA, Dave B, Stricker T, Bhola NE, Silva GO, Patel P, Brantley-Sieders DM, Levin M, Horiates M, Palma NA, Wang K, Stephens PJ, Perou CM, Weaver AM, O'Shaughnessy JA, Chang JC, Park BH, Liebler DC, Cook RS, Arteaga CL (2015) Mol Cell Proteomics 14(7): 1959-76
    › Primary publication · 25953087 (PubMed) · PMC4587316 (PubMed Central)
  5. Quantitative optical imaging of primary tumor organoid metabolism predicts drug response in breast cancer. Walsh AJ, Cook RS, Sanders ME, Aurisicchio L, Ciliberto G, Arteaga CL, Skala MC (2014) Cancer Res 74(18): 5184-94
    › Primary publication · 25100563 (PubMed) · PMC4167558 (PubMed Central)
  6. Molecular profiling of the residual disease of triple-negative breast cancers after neoadjuvant chemotherapy identifies actionable therapeutic targets. Balko JM, Giltnane JM, Wang K, Schwarz LJ, Young CD, Cook RS, Owens P, Sanders ME, Kuba MG, Sánchez V, Kurupi R, Moore PD, Pinto JA, Doimi FD, Gómez H, Horiuchi D, Goga A, Lehmann BD, Bauer JA, Pietenpol JA, Ross JS, Palmer GA, Yelensky R, Cronin M, Miller VA, Stephens PJ, Arteaga CL (2014) Cancer Discov 4(2): 232-45
    › Primary publication · 24356096 (PubMed) · PMC3946308 (PubMed Central)
  7. In vivo hyperspectral imaging of microvessel response to trastuzumab treatment in breast cancer xenografts. McCormack DR, Walsh AJ, Sit W, Arteaga CL, Chen J, Cook RS, Skala MC (2014) Biomed Opt Express 5(7): 2247-61
    › Primary publication · 25071962 (PubMed) · PMC4102362 (PubMed Central)
  8. Genetic and pharmacologic inhibition of EPHA2 promotes apoptosis in NSCLC. Amato KR, Wang S, Hastings AK, Youngblood VM, Santapuram PR, Chen H, Cates JM, Colvin DC, Ye F, Brantley-Sieders DM, Cook RS, Tan L, Gray NS, Chen J (2014) J Clin Invest 124(5): 2037-49
    › Primary publication · 24713656 (PubMed) · PMC4001547 (PubMed Central)
  9. Efferocytosis produces a prometastatic landscape during postpartum mammary gland involution. Stanford JC, Young C, Hicks D, Owens P, Williams A, Vaught DB, Morrison MM, Lim J, Williams M, Brantley-Sieders DM, Balko JM, Tonetti D, Earp HS, Cook RS (2014) J Clin Invest 124(11): 4737-52
    › Primary publication · 25250573 (PubMed) · PMC4347249 (PubMed Central)
  10. CXCR4 drives the metastatic phenotype in breast cancer through induction of CXCR2 and activation of MEK and PI3K pathways. Sobolik T, Su YJ, Wells S, Ayers GD, Cook RS, Richmond A (2014) Mol Biol Cell 25(5): 566-82
    › Primary publication · 24403602 (PubMed) · PMC3937084 (PubMed Central)